Targeting HIF1α Peri-operatively Increased Post-surgery Survival in a Tongue Cancer Animal Model
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Surgery
Link
http://link.springer.com/content/pdf/10.1245/s10434-014-4323-0.pdf
Reference25 articles.
1. Gregoire V, Lefebvre JL, Licitra L, Felip E. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v184–6.
2. Goerner M, Seiwert TY, Sudhoff H. Molecular targeted therapies in head and neck cancer—an update of recent developments. Head Neck Oncol. 2010;2:8.
3. Rivera F, Garcia-Castano A, Vega N, Vega-Villegas ME, Gutierrez-Sanz L. Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial. Expert Rev Anticancer Ther. 2009; 9:1421–8.
4. Schmitz S, Ang KK, Vermorken J, et al. Targeted therapies for squamous cell carcinoma of the head and neck: current knowledge and future directions. Cancer Treat Rev. 2014;40:390–404.
5. Fujii M. Recent multidisciplinary approach with molecular targeted drugs for advanced head and neck cancer. Int J Clin Oncol. 2014;19:220–9.
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Exploring animal models in oral cancer research and clinical intervention: A critical review;Veterinary Medicine and Science;2023-05-17
2. Antitumor effect of the selective hypoxia-inducible factor-1 inhibitors echinomycin and PX-478 on uterine fibroids;F&S Science;2022-05
3. Adjuvant Postoperative CD40 Agonist and PD-1 Antagonist Combination Therapy in Syngeneic Tongue Cancer Mouse Model;Anticancer Research;2020-05
4. ErbB3, a possible prognostic factor of head and neck squamous cell carcinoma;Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology;2020-04
5. Accelerated elimination of human cancer cells by a CD40 agonist antibody combined with a PD‑1 antagonist in CD4‑depleted mice;Oncology Letters;2019-10-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3